Controlling acute elevation of plasma fibrinogen with ancrod

Cerebrovascular Diseases

Volumn 8, Issue SUPPL. 1, 1998, Pages 29-34

  Cole, C Wm ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; FIBRIN; FIBRINOGEN; PROSTACYCLIN; SNAKE VENOM;

BLEEDING; BLOOD VISCOSITY; CONFERENCE PAPER; FIBRINOGEN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; STROKE; THROMBOCYTE AGGREGATION;

ANCROD; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMORHEOLOGY; HUMANS; THROMBOSIS;

EID: 0031963246     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047501     Document Type: Conference Paper

References (32)

1. Ernst E: Plasma fibrinogen - An independent cardiovascular risk factor. J Intern Med 1990; 227:365-373.
2. Smith EB: Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986;15:355-370.
3. Gurewich V, Lipinski B, Hyde E: The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemost 1986;36:604-614.
4. Born GVR, Ernst E, Koenig W, Lowe GDO, Meade TW (eds): Fibrinogen: A 'New' Cardio-vascular Risk Factor. Vienna, Blackwell-MZV, 1992.
5. The Ancrod Stroke Study Investigators: Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-1759.
6. Cole CW, Shea B, Bormanis J: Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma. Can J Surg 1995;38:249-254.
7. Reid HL, Chan K, Thean P: Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963;1621-1626.
8. Esnouf MP, Tunnah GW: The isolation and properties of the thrombin-like activity from Agkistrodon rhodostoma venom. Br J Haematol 1967;13:581-590.
9. Au LC, Lin SB, Chou JS: Molecular cloning and sequence analysis of the cDNA for ancrod, a thrombin-like enzyme from the venom of Calloselasma rhodostoma. Biochem J 1993; 294(pt 2):387-390.
10. Prentice CR, Hampton KK, Grant PJ, Nelson SR, Nieuwenhuizen W, Gaffney PJ: The fibrinolytic response to ancrod therapy: Characterization of fibrinogen and fibrin degradation products. Br J Haematol 1993;83:276-281.
11. Edgar W, Prentice CRM: The proteolytic action of ancrod on human fibrinogen and its polypeptide chains. Thromb Res 1973;2:85-96.
12. Pitney WR, Bell WR, Bolton G: Blood fibrinolytic activity during Arvin therapy. Br J Haematol 1969;16:165-171.
13. Wolf GK: Arvin in peripheral arterial circulatory disorders: Controlled multicentre trials. Eur J Clin Pharmacol 1976;9:387-392.
14. Born GVR, Ernst E, Koenig W, Lowe GDO, Meade TW (eds): Fibrinogen: A 'New' Cardio-vascular Risk Factor. Vienna Blackwell-MZV, 1992, pp 51-54.
15. Bell WR, Shapiro SS, Martinez J, Nossell HL: The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J Lab Clin Med 1978;91:592-604.
16. McKillop C, Edgar W, Forbes CD, Prentice CRM: Possible pathway for formation of fibrin degradation products during ancrod therapy. Nature 1975;255:638-640.
17. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326:800-806.
18. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, et al: Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-542.
19. Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA: Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325.
20. Krishnamurti C, Bolan C, Colleton CA, Reilly TM, Alving BM: Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin. Blood 1993;82:3631-3636.
21. Chang MC, Wang CY, Huang TF: Ancrodformed fibrin stimulates prostacycline production of human umbilical vein endothelial cells via de novo synthesis of cyclooxygenase. Biochem Biophys Res Commun 1994;203:1920-1926.
22. Cole CW, Fournier LM, Bormanis J: Heparinassociated thrombocytopenia and thrombosis: Optimal therapy with ancrod. Can J Surg 1990; 33:207-210.
23. Bell WRJ, Pirkle H, Markland FSJ (eds): Hemostasis and Animal Venoms. New York, Dekker, 1988, pp 541-551.
24. Dormandy JA, Goyle KB, Reid HL: Treatment of severe intermittent claudication by controlled defibrination. Lancet 1977;i:625-626.
25. Wiles PG, Nelson SR, Hampton KK, Casali B, Boothby M, Prentice CRM: Therapeutic defibrinogenation by ancrod: Effect on limb blood flow in peripheral vascular disease. Blood Coagul Fibrinolysis 1990;1:385-388.
26. Lowe GD, Dunlop DJ, Lawson DH: Doubleblind controlled clinical trial of ancrod for ischemic rest pain of the leg. Angiology 1982;33: 46-50.
27. Belch JJF, Meek DR, Lowe GDO, Campbell A, Young AB, Forbes CD, Prentice CRM: Subcutaneous ancrod in prevention of deep vein thrombosis After Hip Replacement Surgery. Thromb Res 1982;25:23-31.
28. Demers C, Ginsberg JS, Brill-Edwards P, Panju A, Warkentin TE, Anderson DR, Turner C, Kelton JG: Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-2197.
29. Zulys VJ, Teasdale SJ, Michel ER, Skala RA, Keating SE, Viger JR, Glynn MFX: Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 1989;71:870-877.
30. Teasdale SJ, Zulys VJ, Mycyk T, Baird RJ, Glynn MFX: Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 1989;48:712-713.
31. Pothoulakis AJ, Neerukonda SK, Ansel G, Jantz RD: Ancrod for coronary angioplasty. Tex Heart Inst J 1995;22:342-346.
32. Latallo ZS: Report of the Task Force on Clinical Use of Snake Venom Enzymes. Thromb Haemost 1978;39:768-774.